# Progress Note 06 — Focused Visit (Care-plan review)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Florence Griffith Joyner (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML033-SYN-TD
- Date: 1996-10-20
- Fictional facility: St. Posthumous Health Center
- Fictional author: Celeste Vanterpool, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Visit type: Focused Visit (Care-plan review)

## Chief complaint

Six months after the seizure: seizure freedom, driving review, training, and the long-term plan. **S**

## History of present illness

Ms. Griffith Joyner returns six and a half months after the seizure on the flight and four months after lesionectomy. She has had no seizure or spell and no detection-watch alert. She takes levetiracetam twice a day and folic acid daily without side effects. She is back to full sprint training, has swum with a companion, and is flying for work again. She has not driven and asks when she can. She is not planning a pregnancy in the next year. She has had no thoughts of self-harm. **S**

| Element | Detail |
|---|---|
| Seizures | None for six and a half months |
| Training | Full sprint training |
| Driving | Not driving; asks about returning |
| Levetiracetam | Taken as prescribed; no side effects |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | Energetic; no weight change |
| Neurological | Negative | No seizures, spells, headache or weakness |
| Musculoskeletal | Negative | Training without injury |
| Psychiatric | Negative | Mood good; PHQ-9 2; no thoughts of self-harm |

4 systems reviewed. **S**

## Current medications

- Levetiracetam 500 mg oral tablet, one tablet by mouth twice daily **S**
- Folic acid 0.4 mg oral tablet, one tablet daily **S**

## Allergies

- No known allergy **S**

## Objective

BP 110/70 mmHg; pulse 54 bpm; respirations 14/min; temperature 36.6 °C; oxygen saturation 99% on room air; weight 60.9 kg; BMI 21.1 kg/m². All vital signs are synthetic.

PHQ-9: 2. All results are synthetic.

## Physical examination

| System | Finding |
|---|---|
| General | Fit and well; weight 60.9 kg; blood pressure 110/70, pulse 54 |
| Neurological | Alert and oriented; cranial nerves, strength, coordination and gait normal |
| Psychiatric | Cheerful and engaged |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Focal epilepsy with structural cause, seizure-free after lesionectomy** (G40.209). Seizure-free for six and a half months on levetiracetam, four months after complete lesionectomy. In California the decision to drive rests with the DMV, which reviews her physician's report of seizure control; she meets the usual seizure-free period for its review. Levetiracetam continues for at least two years after surgery; a taper would then be a shared decision with the epilepsy team, with an EEG first. **S**
   - Medical report to the DMV supporting a review of her driving, at her request.
   - Continue levetiracetam 500 mg twice daily and folic acid.
   - Keep the detection watch and the water safety rules for now.
   - Plan any pregnancy with the epilepsy team; levetiracetam can continue in pregnancy.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Self-management | Seizure diary and adherence | Each visit | Completed today | No seizure for six and a half months; no watch alerts; every dose taken |
| Survey | Mood and behavior on levetiracetam (PHQ-9) | Before starting and at each visit | Completed today | PHQ-9 2 |
| Self-management | Driving restriction and the California physician report | Until cleared by the DMV | Completed today | Medical report sent today, at her request, for the DMV's review |
| Imaging | Repeat MRI | After complete resection, only for new symptoms | Not indicated | Complete resection and no symptoms |
| Imaging | Repeat EEG | Before any taper of antiseizure medication | Not indicated | No taper is planned for at least two years |
| Self-management | Nocturnal seizure detection | While on treatment after recent seizures | Completed today | Continues by her choice |
| Self-management | SUDEP risk review | Each visit | Completed today | No tonic-clonic seizure for six and a half months, the main protection; she knows the plan |
| Medication safety | Folic acid, contraception and pregnancy planning | Each visit | Completed today | No pregnancy planned this year; plan with the epilepsy team |

## Goal progress

- EEG and MRI with susceptibility-weighted imaging within one week, and an epilepsy consultation within two weeks. Outcome by 1996-05-05: EEG in two days, MRI in six, consultation at two weeks. **S**
- No further seizures on an antiseizure medication she tolerates. Outcome by 1996-10-20: No seizure in six months; levetiracetam tolerated after early irritability settled. **S**
- Neurosurgical evaluation of the cavernous malformation and a shared decision about lesionectomy within two months. Outcome by 1996-07-21: Seen by neurosurgery at three weeks; complete lesionectomy at eight weeks. **S**
- Safety plan in place: no driving until cleared, water and height safety, SUDEP discussion, and a nocturnal seizure detection plan. Outcome by 1996-05-27: Driving stopped and reported as California requires; SUDEP discussed (one visit late, recorded as a deviation); detection watch in use. **S**
- Graded return to full sprint training within four months of surgery. Outcome by 1996-10-20: Full training at four months after surgery. **S**

## Guideline basis

- Krumholz A, et al. Evidence-based guideline: Management of an unprovoked first seizure in adults. Neurology 2015;84(16):1705-1713 (PMID 25901057) (2015), American Academy of Neurology and American Epilepsy Society
- Akers A, et al. Synopsis of Guidelines for the Clinical Management of Cerebral Cavernous Malformations: Consensus Recommendations Based on Systematic Literature Review by the Angioma Alliance Scientific Advisory Board Clinical Experts Panel. Neurosurgery 2017;80(5):665-680 (PMID 28387823) (2017), Angioma Alliance (Neurosurgery)
- Harden C, et al. Practice guideline summary: Sudden unexpected death in epilepsy incidence rates and risk factors. Neurology 2017;88(17):1674-1680 (PMID 28438841) (2017), American Academy of Neurology and American Epilepsy Society
- Pack AM, et al. Teratogenesis, Perinatal, and Neurodevelopmental Outcomes After In Utero Exposure to Antiseizure Medication: Practice Guideline From the AAN, AES, and SMFM. Neurology 2024;102(11):e209279 (PMID 38748979) (2024), American Academy of Neurology, American Epilepsy Society and Society for Maternal-Fetal Medicine
- Beniczky S, et al. Automated seizure detection using wearable devices: A clinical practice guideline of the International League Against Epilepsy and the International Federation of Clinical Neurophysiology. Epilepsia 2021;62(3):632-646 (PMID 33666944) (2021), International League Against Epilepsy and International Federation of Clinical Neurophysiology
- Governor's message returning Senate Bill 357 without signature (physician reporting of disorders characterized by lapses of consciousness remains mandatory under Health and Safety Code section 103900) (2024), Office of the Governor of California
- Depression and Suicide Risk in Adults: Screening (2023), U.S. Preventive Services Task Force

## Follow-up

- Epilepsy review in six months; primary care preventive visit yearly. Call at once for any seizure; no driving until the DMV clears her. **S**

